Blueprint Medicines (NASDAQ:BPMC) Upgraded to “Outperform” at Oppenheimer
Oppenheimer upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a market perform rating to an outperform rating in a report issued on Friday, MarketBeat.com reports. The brokerage currently has $85.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on BPMC. StockNews.com initiated coverage on shares of […]
More Stories
CCL Industries (TSE:CCL.B) Sets New 1-Year High at $74.56
CCL Industries Inc. (TSE:CCL.B – Get Free Report) hit a new 52-week high during trading on Wednesday . The company...
Pine Cliff Energy (TSE:PNE) Sets New 12-Month Low at $0.90
Shares of Pine Cliff Energy Ltd. (TSE:PNE – Get Free Report) hit a new 52-week low during trading on Wednesday...
Sernova (TSE:SVA) Reaches New 52-Week Low at $0.28
Sernova Corp. (TSE:SVA – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The...
Cadence Bank Purchases 915 Shares of Tyson Foods, Inc. (NYSE:TSN)
Cadence Bank boosted its position in shares of Tyson Foods, Inc. (NYSE:TSN – Free Report) by 5.6% in the first...
Advisors Asset Management Inc. Acquires 413 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY)
Advisors Asset Management Inc. lifted its position in O’Reilly Automotive, Inc. (NASDAQ:ORLY – Free Report) by 15.5% in the 1st...
Cadence Bank Cuts Holdings in The Goldman Sachs Group, Inc. (NYSE:GS)
Cadence Bank cut its holdings in The Goldman Sachs Group, Inc. (NYSE:GS – Free Report) by 10.4% during the first...